1. Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts. (29th August 2018) Authors: Bota, Daniela A; Chung, Jinah; Dandekar, Manisha; Carrillo, Jose A; Kong, Xiao-Tang; Fu, Beverly D; Hsu, Frank PK; Schönthal, Axel H; Hofman, Florence M; Chen, Thomas C; Zidovetzki, Raphael; Pretto, Chrystel; Strik, Ankie; Schijns, Virgil EJC; Stathopoulos, Apostolos Journal: CNS oncology Issue: Volume 7:Number 3(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗